Heinz Body Hemolytic Anemia Induced by DQ-2511, a New Anti-ulcer Drug, in Dogs

ArticleinFundamental and Applied Toxicology 20(2):141-6 · March 1993with11 Reads
DOI: 10.1006/faat.1993.1019 · Source: PubMed


    DQ-2511, a new anti-ulcer drug, was administered to beagle dogs for 4 weeks to investigate the mechanism whereby this drug
    induced hemolytic anemia and its reversibility in comparison with β-acetylphenylhydrazine. Hemolytic anemia accompanied by
    an increase in the number of cells containing Heinz bodies that was preceded by a marked decrease in blood-reduced glutathione
    concentration was observed in dogs receiving 600 mg/kg of DQ-2511, but only a slight increase in the methemoglobin level was
    noted.β-Acetylphenylhydrazine, however, caused hemolytic anemia accompanied by marked increases in both Heinz body-containing
    cells and methemoglobin concentration, but the blood-reduced glutathione concentration was not decreased consistently with
    the formation of Heinz bodies. Hemolytic anemia disappeared after a 4-week recovery period in the dogs that received DQ-2511.
    These results suggest that decreases in reduced glutathione in erythrocytes play an important role in the anemia and Heinz
    body formation induced by DQ-2511, but not by β-acetylphenylhydrazine.